CL2017002661A1 - Método de producción de gonadotrofina - Google Patents

Método de producción de gonadotrofina

Info

Publication number
CL2017002661A1
CL2017002661A1 CL2017002661A CL2017002661A CL2017002661A1 CL 2017002661 A1 CL2017002661 A1 CL 2017002661A1 CL 2017002661 A CL2017002661 A CL 2017002661A CL 2017002661 A CL2017002661 A CL 2017002661A CL 2017002661 A1 CL2017002661 A1 CL 2017002661A1
Authority
CL
Chile
Prior art keywords
production method
gonadotrophin
gonadotrophin production
host cell
hcg
Prior art date
Application number
CL2017002661A
Other languages
English (en)
Inventor
Daniel Plaksin
Ayelet Grinhut
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2017002661A1 publication Critical patent/CL2017002661A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>Una célula huésped caracterizada porque la misma comprende una secuencia que codifica para la cadena α de hCG integrada en su genoma, y el uso de dicha célula huésped para producir hCG recombinante.</p>
CL2017002661A 2015-04-24 2017-10-19 Método de producción de gonadotrofina CL2017002661A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15164965 2015-04-24

Publications (1)

Publication Number Publication Date
CL2017002661A1 true CL2017002661A1 (es) 2018-03-23

Family

ID=53002568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002661A CL2017002661A1 (es) 2015-04-24 2017-10-19 Método de producción de gonadotrofina

Country Status (32)

Country Link
US (1) US10464984B2 (es)
EP (1) EP3286209B1 (es)
JP (1) JP6964519B2 (es)
KR (1) KR102658666B1 (es)
CN (2) CN107532172A (es)
AU (1) AU2016251314B2 (es)
BR (1) BR112017016895A2 (es)
CA (1) CA2975449A1 (es)
CL (1) CL2017002661A1 (es)
CO (1) CO2017011964A2 (es)
DK (1) DK3286209T3 (es)
EA (1) EA034022B1 (es)
ES (1) ES2837111T3 (es)
HK (1) HK1246325A1 (es)
HR (1) HRP20201945T1 (es)
HU (1) HUE051879T2 (es)
IL (1) IL253694B (es)
LT (1) LT3286209T (es)
MA (1) MA41949B1 (es)
MD (1) MD3286209T2 (es)
MX (1) MX2017010884A (es)
MY (1) MY185823A (es)
PH (1) PH12017501585A1 (es)
PT (1) PT3286209T (es)
RS (1) RS61163B1 (es)
SA (1) SA517390029B1 (es)
SG (1) SG11201706832PA (es)
SI (1) SI3286209T1 (es)
TN (1) TN2017000328A1 (es)
UA (1) UA124187C2 (es)
WO (1) WO2016170113A1 (es)
ZA (1) ZA201707136B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904787T3 (es) 2017-09-01 2022-04-06 Ferring Bv Composición para la estimulación ovárica controlada
CN108264549A (zh) * 2018-03-29 2018-07-10 北京伟杰信生物科技有限公司 重组绒促性素rhCG的制备方法及应用
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
CN110812366B (zh) * 2019-11-18 2023-11-17 珠海丽凡达生物技术有限公司 一种可用于激素补充的mRNA药物及其制备方法
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2001058493A1 (en) * 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
CN1194016C (zh) * 2000-12-29 2005-03-23 申庆祥 新的人绒毛膜促性腺激素－促黄体素融合蛋白及其制法和用途
CN101250531B (zh) * 2006-11-27 2013-04-24 株式会社Lg生命科学 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞及利用该细胞生产人fsh的方法
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US8326547B2 (en) * 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
JP2013526840A (ja) * 2009-12-21 2013-06-27 ファーマシーネ，インコーポレイテッド 組み換えブチリルコリンエステラーゼおよびその切断型
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN103539862B (zh) * 2013-11-01 2015-04-01 广州联康生物科技有限公司 一种长效重组促卵泡激素及其应用

Also Published As

Publication number Publication date
SA517390029B1 (ar) 2021-04-04
IL253694B (en) 2021-09-30
JP6964519B2 (ja) 2021-11-10
PT3286209T (pt) 2020-12-04
EP3286209A1 (en) 2018-02-28
EA201791724A1 (ru) 2018-04-30
HK1246325A1 (zh) 2018-09-07
SG11201706832PA (en) 2017-09-28
CO2017011964A2 (es) 2018-03-09
ZA201707136B (en) 2022-03-30
CA2975449A1 (en) 2016-10-27
EP3286209B1 (en) 2020-11-25
LT3286209T (lt) 2021-02-25
MX2017010884A (es) 2017-12-07
HUE051879T2 (hu) 2021-03-29
WO2016170113A1 (en) 2016-10-27
RS61163B1 (sr) 2021-01-29
SI3286209T1 (sl) 2021-01-29
MY185823A (en) 2021-06-11
MD3286209T2 (ro) 2021-04-30
DK3286209T3 (da) 2020-12-21
PH12017501585A1 (en) 2018-02-05
UA124187C2 (uk) 2021-08-04
JP2018512885A (ja) 2018-05-24
HRP20201945T1 (hr) 2021-02-05
TN2017000328A1 (en) 2019-01-16
AU2016251314A1 (en) 2017-08-17
MA41949A (fr) 2018-02-28
US20180127477A1 (en) 2018-05-10
IL253694A0 (en) 2017-09-28
CN107532172A (zh) 2018-01-02
AU2016251314B2 (en) 2019-12-05
EA034022B1 (ru) 2019-12-19
ES2837111T3 (es) 2021-06-29
MA41949B1 (fr) 2020-12-31
BR112017016895A2 (pt) 2018-03-27
KR20170138390A (ko) 2017-12-15
CN114107315A (zh) 2022-03-01
KR102658666B1 (ko) 2024-04-17
US10464984B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
CL2017002661A1 (es) Método de producción de gonadotrofina
CL2017002161A1 (es) Jarabes de alulosa
CL2017000752A1 (es) Procedimiento para producir biomasa que tiene un alto contenido de exopolisacáridos
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
CL2017001632A1 (es) Manufactura de proteína.
CO2017000416A2 (es) Una composición hidráulica
AR102527A1 (es) Vacunas terapéuticas para hpv16
CR20150112S (es) Botella
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
CL2017000092A1 (es) Contenedor flexible con accesorios y proceso para producirlo
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
CR20130447S (es) Botella
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
AR100050A1 (es) Proceso para acidificación usando formulaciones ácidas retardadas
CR20150110S (es) Botella
CR20130448S (es) Botella
CR20150113S (es) Botella
MY183321A (en) Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
AR096879A1 (es) Diutano como modificador de la reología en cementos sorel
UY34268A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico